Microdosing vs Clinical Treatment

Safety first. Neither microdosing nor any psychedelic is a proven treatment you can start on your own. If you have a mental health condition, take psychiatric medicines, are pregnant, or have heart disease, talk with a licensed clinician before any change; never stop a prescribed medicine on your own. In a US mental health crisis call or text 988; in a medical emergency call 911. US Poison Help is 1-800-222-1222. This page is education only and gives no amounts, schedules or advice to microdose.

Evidence labels used here: approved medicine, promising but limited, mixed, insufficient evidence, marketing claim. Where we looked and found nothing usable, we write "Proper evidence not found."

Definitions

• Microdosing means regularly taking very small amounts of a psychedelic, usually LSD or psilocybin, aiming to stay below noticeable hallucinogenic effects. People say they do it to ease depression or stress, improve productivity or ease pain. NIDA states that research to date has not established whether microdosing is safe or effective. [1][2] A review notes there is no agreed scientific consensus on what microdosing is. [3]
• Clinical treatment in research means giving a psychedelic or related drug under medical supervision, usually in one to three sessions combined with counseling. NIDA adds that only esketamine, a ketamine derivative, is FDA approved for therapeutic use among these drugs. [1]

Side-by-side

What research shows

Microdosing: mixed to insufficient evidence.

• Controlled studies tend to find little. A systematic review of 24 studies (3,681 people) concluded that microdosing does not show consistent immediate benefits for depression, anxiety or stress in healthy adults, and RCT evidence remains inconclusive. [9]
• In a self-blinding study with 191 completers, the placebo group improved as much as the microdosing group, and many participants broke the blind. [4]
• In a 2026 umbrella review the only significant pooled effect was a small decrease in cognitive control; reported mood benefits were largely reduced under placebo-controlled conditions. [10]
• A randomized trial of repeated low-dose LSD in 53 adults found it safe in an outpatient setting but no better than placebo for ADHD symptoms. [11]
• Observational studies report more benefits but are shaped by expectation and who chooses to take part. [9]

Clinical treatment: promising but limited, not approved.

• A 104-person trial found psilocybin lowered depression scores more than niacin, with more adverse events. [8]


• Dose-comparison phase 2 trial in treatment-resistant depression: benefit at 3 weeks for the higher dose, no support for sustained response at 12 weeks, adverse events in 77%. [7]


• Trial effect sizes may be overstated because of unblinding and high expectations. [12]

So neither is proven, but the two are not the same kind of evidence. Supervised studies check eligibility, record adverse events, and use a defined product.

Risks

• Microdosing: long-term effects are unknown. Reviewers worry that LSD and psilocybin resemble drugs that raised the risk of heart-valve problems when taken regularly, and note long-term cardiac effects remain unknown. [5] Adverse effects such as anxiety and cognitive disruption are also reported. [13]
• Unregulated products: US poison-center data show unpredictable effects from mushroom edibles. [6]
• Clinical: adverse events are common, and trials often exclude people at higher risk, so real-world safety is less certain. [1]

Legal note

Laws differ by country and state and change; this is not legal advice. In the United States, psilocybin and LSD appear in Schedule I of 21 CFR 1308.11 (read 2026-10-22). [14] Other places: not verified. See legal status by country.

No universal winner

Microdosing is not a lower-risk version of clinical treatment, and clinical treatment is not a proven cure. Read more: what is microdosing, human microdosing research and how to read a psychedelic clinical trial.